ArticleHead & neck2019
HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.
Article in Head & neck, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.Nature communications · 2021Trial
- Major histocompatibility complex II serves as a prognostic biomarker in resectable pulmonary sarcomatoid carcinoma: development of a prediction model.Translational lung cancer research · 2026Article
- Biological mechanism and immune response of MHC-II expression in tumor cells.Cancer biology & medicine · 2025Review
- Therapeutic options for human papillomavirus-positive tonsil and base of tongue cancer.Journal of internal medicine · 2025Review
- Hypothesis of a CD137/Eomes activating axis for effector T cells in HPV oropharyngeal cancers.Molecular medicine (Cambridge, Mass.) · 2024Article
- Fibroblasts from HPV-negative oropharynx squamous cell carcinomas stimulate the release of osteopontin from cancer cells via the release of IL-6.Frontiers in oral health · 2024Article
- Major histocompatibility complex class II in the tumor microenvironment: functions of nonprofessional antigen-presenting cells.Current opinion in immunology · 2023Review
- Targeted spatial proteomic analysis of CD8Frontiers in oncology · 2023Article
- Reduced MHC Class I and II Expression in HPV-Negative vs. HPV-Positive Cervical Cancers.Cells · 2022Article
- Oral Papillomatosis: Its Relation with Human Papilloma Virus Infection and Local Immunity-An Update.Medicina (Kaunas, Lithuania) · 2022Review
- Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant Melanoma.Cancers · 2021Article
- Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.Journal for immunotherapy of cancer · 2021Article
- Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors.Viruses · 2021Review
- Review
- Distinct Patterns of Myeloid Cell Infiltration in Patients With hrHPV-Positive and hrHPV-Negative Penile Squamous Cell Carcinoma: The Importance of Assessing Myeloid Cell Densities Within the Spatial Context of the Tumor.Frontiers in immunology · 2021Article
- Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.International journal of molecular sciences · 2020Review
- High MHC-II expression in Epstein-Barr virus-associated gastric cancers suggests that tumor cells serve an important role in antigen presentation.Scientific reports · 2020Article
- CD163Journal for immunotherapy of cancer · 2020Article
- The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma.Frontiers in oncology · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundHuman papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is a highly immunogenic tumor and differences in tumor microenvironment might contribute to the improved survival of HPV-positive OPSCC patient.
methodsA comprehensive multivariate analysis with clinical and immune variables (human leukocyte antigen [HLA] I/II, programmed death ligand 1 (PD-L1), programmed death receptor 1 (PD1), T cells, and macrophages) was performed in 142 OPSCC patients.
resultsWe found an inverse correlation between the expression of HLA class II molecules on tumor cells and CD68+ CD163+ tumor-associated macrophages (TAMs). High HLA-DP/DQ/DR expression and low number of TAMs were associated with longer disease-specific survival and disease-free survival (DFS). Furthermore, a new population of CD8+ FoxP3+ T cells was correlated with shorter DFS in multivariate analysis.
conclusions\We identified new prognostic markers for patients with oropharyngeal cancer, which can be used for selecting patients that can benefit from immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.